Posted by Michael Wonder on 05 Mar 2026
Hemab Therapeutics receives FDA breakthrough therapy designation for sutacimig in Glanzmann thrombasthenia
5 March 2026 - Sutacimig has potential to become a first in class prophylactic treatment for Glanzmann thrombasthenia, an inherited serious bleeding disorder.
Hemab Therapeutics today announced that the US FDA has granted breakthrough therapy designation for sutacimig for the prevention of bleeding episodes in patients with Glanzmann thrombasthenia.
